Product Images Atorvastatin Calcium

Atorvastatin Calcium is a prescription medication manufactured by Accord Healthcare Inc. It is only available with a doctor's prescription and comes in the form of tablets. Its NDC number is 70518-1977-01 and it should be kept out of reach of children. Directions for use can be found in the package insert, and it should be stored between 20-26°C (63-77°F), with permitted excursions between 15-30°C (59-86°F) as per USP guidelines. It was repackaged by RemedyRepack Inc. of Indiana.*

Atorvastatin Calcium is a prescription drug manufactured by Accord Healthcare, Inc. The National Drug Code (NDC) for this medication is 70518-1977-02. The source NDC is 16729-0045-17. The medication should be kept out of the reach of children. The package should be stored at 20-26°C (63-77°F) and excursions are permitted to 15-30°C (59-86°F) according to USP. The package insert should be consulted for directions of use. The medication has been repackaged by RemedyRepack Inc., Indiana, PA 15701.*

Atorvastatin Calcium is a prescription medication manufactured by Accord Healthcare, Inc. The NDC number is 70518-1977-00 and the source NDC is 16729-0045-17. The medication expires, and the lot number is not available. The directions for use are provided in the package insert. The medication must be stored at 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F), in accordance with USP requirements. RemedyRepack Inc., Indiana, repackaged this medication. Keep it out of the reach of children.*

This appears to be a graph or chart related to a clinical trial comparing the efficacy of a placebo versus Atorvastatin in reducing the cumulative hazard percentage for a primary endpoint over four years of follow-up. It shows the hazard percentage for both groups at different time points and indicates that Atorvastatin was associated with a statistically significant reduction in hazard compared to the placebo.*

This is a brief excerpt from a clinical trial report, showing the percentage of subjects experiencing cardiac events while taking Atorvastatin at two different doses (10 mg and 80 mg). It also provides a hazard ratio (HR) calculated for the two dosages in relation to the risk of having a major cardiovascular event, such as a heart attack or stroke, over a period of up to five years. However, the full context and details of the study are not available from this text alone.*